GlaxoSmithKline PLC brings more certainty to its consumer health business plans, potentially including shedding lagging brands and product lines, by acquiring full control of the OTC drug and nutritional products joint venture it has operated with Novartis AG.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?